PYY 3-36 (Peptide YY)
Gut-derived peptide. Truncated form (3-36) is the postprandial satiety signal — binds Y2 receptors in the arcuate nucleus to suppress NPY-driven appetite. Adjacent + complementary to GLP-1 pathway.
How it clearsHalf cleared in ~15min. Most (~96%) gone by ~1.3h.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Batterham 2002 NEJM showed acute IV PYY 3-36 reduced ad-libitum caloric intake by ~30% in healthy + obese subjects — the foundational human-trial paper. Subsequent intranasal + injectable formulations have been tested but no FDA-approved product exists; the molecule is short-acting and hard to formulate. Grey-market peptide use exists in the GLP-1-plus-PYY satiety-stacking community. Novo Nordisk explored long-acting PYY analogs as potential GLP-1 adjuncts but no late-stage candidates have advanced.
Short half-life makes consistent dosing difficult — pharma development stalled at this problem. Nausea + GI side effects scale fast at functional doses, similar to GLP-1 titration. Stacking with GLP-1s adds class-additive nausea + dehydration risk. Identity verification of grey-market PYY 3-36 is poor.
Upload your data to see how it relates to PYY 3-36.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
PYY 3-36 (Peptide YY) — primary mechanism: gut-derived peptide. truncated form (3-36) is the postprandial satiety signal — binds y2 receptors in the arcuate nucleus to suppress npy-driven appetite. adjacent + complementary to glp-1 pathway.
2 supporting referencesVerified 13d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Research-grey · no FDA-approved formulation · grey-market peptide for stack adjunct
Pre-filled with this compound's published dose range: 100-500 mcg (grey-market subcutaneous) · pre-meal, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.